ECE2010 Poster Presentations Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>) (82 abstracts)
RET mutation screening in multiple endocrine neoplasia type 2 (MEN2) and medullary thyroid carcinoma patients (MTC) in Romania
Diana Loreta Paun 1, , Serban Radian 1, , Laura Iconaru 1, , Corin Badiu 1, , Daniel Grigorie 1, , Ileana Marinescu 1 , Mihai Coculescu 1, & Constantin Dumitrache 1,
1C.I. Parhon National Institute of Endocrinology, Bucharest, Romania; 2C. Davila University of Medicine, Department of Endocrinology, Bucharest, Romania.
Background: According to current guidelines, RET mutation screening is indicated for MEN2 and familial MTC (FMTC) kindreds, as well as for apparently sporadic MTC patients.
Aim: To investigate RET mutations in Romanian MEN2, FMTC and sporadic MTC cases.
Patients and methods: RET mutation screening was performed by high-resolution melting analysis followed by direct sequencing of PCR products of exons 10-11 in 7 MEN2A families, 2 FMTC families and 25 apparently sporadic MTC patients.
Results: In all MEN2A families (27 tested individuals) a RET mutation was present (4 Cys634Trp and 3 Cys634Arg). All subjects with clinical or biochemical disease (15) were positive for RET mutation. 5 asymptomatic carriers were identified and 7 subjects at risk were negative for their respective family mutations. Prophylactic thyroidectomy was proposed to asymptomatic carriers and to pheochromocytoma-only individuals. Five subjects accepted and three denied thyroidectomy. In one FMTC family we found a Cys634Tyr mutation in 2 affected individuals, while in the other FMTC family there was no RET mutation (3 individuals tested). Only one sporadic MTC patient had a RET mutation (Cys634Arg). Screening for this mutation in the patients’ family is pending.
Discussion: We detected a low number of asymptomatic mutation carriers, mainly because of poor acceptance of screening by non-affected individuals.
Conclusions: RET mutation screening should be performed in MEN2 / FMTC families and sporadic MTC. We are extending screening to exons 13–16 in our sporadic MTC cohort.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more